ChemoCentryx
Biotechnology Research • 
Redwood City, California, United States • 21-50 Employees
Company overview
| Headquarters | 835 Industrial Road, Suite 600, San Carlos, California 94070, US |
| Phone number | +16502102900 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Biopharmaceutical, Pancreatic Cancer, Drug Discovery, Immuno-Oncology, Chronic Kidney Disease, Autoimmune Diseases, Anca-Associated Vasculitis, Inflammatory Disorders, Orphan And Rare Diseases, Rheumatoid Arthritis (Ra), Diabetic Nephropathy, Advocate, Inflammatory Bowel Disease (Ibd), Hidradenitis Suppurativa, Aurora, Avacopan, C3 Glomerulopathy, Chemoattractant System, Chemokine, Complement Receptor, Small Molecule Therapeutics, Oral Therapeutics, Lumina, Tavneos |
| Founded | 1997 |
| Employees | 21-50 |
| Socials |
Key Contacts at ChemoCentryx
Nikhil Mehta
Senior Director, Training & Developmemt
Surender Goli
Associate Director, G&A Business Applications
Wen Zhang
Director, Statistical Programming
Helen Wang
Director
Dale Newland
Associate Director, Facilities, Safety Officer
Thomas Edwards
Director
ChemoCentryx Email Formats
ChemoCentryx uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@chemocentryx.com), used 66.7% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@chemocentryx.com | 66.7% |
{first name}{last name} | johndoe@chemocentryx.com | 23.8% |
{first initial}{first initial} | jj@chemocentryx.com | 4.8% |
{last name} | doe@chemocentryx.com | 4.8% |
About ChemoCentryx
ChemoCentryx, Inc. (NASDAQ: CCXI) is a biopharmaceutical company founded in 1997 commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the first approved orally administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa (HS) and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Our goal is to change treatment paradigms in orphan and rare disease—specifically targeting the chronic inflammatory pathway while avoiding immuno-suppression. TAVNEOS, our first commercial drug product, and each of our drug candidates are designed to selectively block a specific chemoattractant receptor. We balance our passion for science with the deep-seated belief that patients suffering from serious diseases deserve more than incremental improvements to the length and quality of their lives.
ChemoCentryx revenue & valuation
| Annual revenue | $37,300,000 |
| Revenue per employee | $794,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $119,300,000 |
| Total funding | $325,400,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
ChemoCentryx has 19 employees across 8 departments.
Departments
Number of employees
ChemoCentryx Tech Stack
Discover the technologies and tools that power ChemoCentryx's digital infrastructure, from frameworks to analytics platforms.
PaaS
Reverse proxies
Webmail
CDN
Font scripts
Miscellaneous
Belgium
Israel
Frequently asked questions
4.8
40,000 users
